An Open-label Phase Ib/II, Multi-center Study of 4SC-202 in Combination With Pembrolizumab in Patients With Unresectable Stage III/Metastatic Stage IV Cutaneous Melanoma Primary Refractory/Non-responding to Prior Anti-PD-1 Therapy

Trial Profile

An Open-label Phase Ib/II, Multi-center Study of 4SC-202 in Combination With Pembrolizumab in Patients With Unresectable Stage III/Metastatic Stage IV Cutaneous Melanoma Primary Refractory/Non-responding to Prior Anti-PD-1 Therapy

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 02 Dec 2017

At a glance

  • Drugs 4SC 202 (Primary) ; Pembrolizumab (Primary)
  • Indications Malignant melanoma
  • Focus Adverse reactions
  • Acronyms SENSITIZE
  • Sponsors 4SC
  • Most Recent Events

    • 06 Nov 2017 According to a 4SC media release, the first patient has been enrolled in this trial. Prof. Dirk Schadendorf is the principal investigator of this trial. Top-line results from this trial are expected in H2 2018.
    • 26 Oct 2017 According to a 4SC media release, After opening the first clinical center in Q3 2017, company is anticipating to enroll the first patient in Q4 2017.
    • 04 Oct 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top